<DOC>
	<DOCNO>NCT01138839</DOCNO>
	<brief_summary>The purpose study determine efficacy dexamethasone treatment HELLP I ( hemolysis , elevate liver enzymes low platelet count ) syndrome .</brief_summary>
	<brief_title>Dexamethasone Efficacy HELLP I Syndrome</brief_title>
	<detailed_description>Treatment HELLP syndrome usually restrict measure support treatment complication . In 2005 , subgroup analysis show , among patient HELLP 1 , short average time platelet recovery less duration hospitalization woman receive dexamethasone therapy , however importance find diminish unplanned analysis severity disease take account randomization .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HELLP Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Women &gt; 20 week gestation first 3 day puerperium hypertension develop pregnancy puerperium : platelet count , &lt; = 50,000/mm3 ; aspartate aminotransferase ( AST ) , &gt; = 70 U/L ; lactate dehydrogenase ( LDH ) , &gt; = 600 U/L . Women consent include informed consent signature diabetic ketoacidosis oral temperature &gt; 37.5 grade Contraindication use steroid</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HELLP 1</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Clinical trial</keyword>
</DOC>